Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26

Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $20 to $26.